VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives

Author(s): Toni K. Choueiri

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 6 , Issue 3 , 2011


Metastatic renal cell carcinoma (RCC) is predominantly refractory to treatment with traditional cytotoxic chemotherapies, and until recently management options were limited to immunotherapy, palliative care, or phase I trials. The past five years have witnessed a major change in the treatment of advanced RCC with the introduction of targeted therapies that derive their efficacy through affecting angiogenesis. The main class of agents involves drugs that target the vascular endothelial growth factor (VEGF). Several VEGF inhibitors are now approved for the treatment of metastatic RCC. The field is expanding rapidly with goals including 1) developing novel more potent and better tolerated agents and 2) defining the role of combination and sequential anti-VEGF regimens.

Keywords: Renal cell carcinoma, VEGF, angiogenesis, targeted therapy, Sorafenib, Tivozanib, Dovitinib, Aflibercept, Ramucirumab, Linifanib

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [164 - 168]
Pages: 5
DOI: 10.2174/157488411797189424
Price: $65

Article Metrics

PDF: 9